Tag: C.HUGE

Recreational Cannabis in Canada

JayCurrie
Canada gold, junior mining companies

Here is another in my series of articles on the recreational marijuana industry in Canada. There is no doubt a lot of money to be made selling legal pot but the federal and provincial governments are not making it easy. The biggest hole in the regulatory scheme is the postponement of regulations dealing with edibles. In the US edibles have constituted up to 50% of the legal market. Companies have to adapt. read more

FSD Pharma secures exclusive rights in Canada for line of proprietary products and premium access to cannabinoid science research platform in Israel

MotherlodeTV

FSD Pharma Inc. (the “Company”) (CSE: HUGE), is pleased to announce that its wholly- owned subsidiary FV Pharma Inc (“FV Pharma”) have entered into a strategic alliance with SciCann Therapeutics Inc. (“SciCann”) by executing a binding Memorandum of Understanding  (the “MOU“) dated May 28, 2018, pursuant to which FV Pharma shall invest up to $3M in SciCann for a 15% equity stake. read more

C.HUGE All-Time Daily Volume Record Broken and Thanks to All Shareholders

JayCurrie
Canada gold, junior mining companies
TORONTO, May 30, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that on its first day of trading (May 29, 2018) the company traded exactly 78,477,861 Class B subordinate voting shares on the CSE (Canadian Securities Exchange), 7,592,500 on AQC-Lit, 1,680,000 on AQC-Neo, 136,000 on CHIX, 236,500 on CX2 and 25,013,000 on the TriAct exchange for an aggregate total of 113,135,861 shares traded. This is the largest total quantity of share volume traded by a CSE listed issuer by over 27% above the recorded all-time high of 88,846,729, on the first day of trading, as confirmed by the CSE.The company wishes to thank all its shareholders and stakeholders for their support to date, which has resulted in a record-breaking launch into the Canadian cannabis marketplace.About FSD Pharma Inc.FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FSD Pharma’s management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development. Please visit www.fsdpharma.com for more information.Forward-Looking InformationCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.Thomas FairfullChief Executive Director, FSD Pharma Inc.SOURCE FV Pharma IncFor further information: Investor Relations, Phone : 416-433-2166, Email:IR@fsdpharma.com, Website: www.fsdpharma.com